Galmed Pharmaceuticals analyst ratings
Galmed Pharmaceuticals analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2022 | 120.99% | Canaccord Genuity | $5 → $1 | Downgrades | Buy → Hold |
| 05/18/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 05/03/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/03/2022 | 1004.97% | Raymond James | $14 → $5 | Maintains | Outperform |
| 05/17/2021 | 4540.88% | Canaccord Genuity | $20 → $21 | Maintains | Buy |
| 03/19/2021 | 5424.86% | HC Wainwright & Co. | $29 → $25 | Maintains | Buy |
| 01/08/2021 | 3656.91% | Raymond James | $20 → $17 | Maintains | Outperform |
| 11/25/2020 | 4319.89% | Canaccord Genuity | $25 → $20 | Maintains | Buy |
| 05/22/2020 | 1667.96% | B. Riley Securities | $11 → $8 | Downgrades | Buy → Neutral |
| 05/15/2020 | 4319.89% | Raymond James | $25 → $20 | Maintains | Outperform |
| 03/13/2020 | 5424.86% | Stifel | $35 → $25 | Maintains | Buy |
| 03/13/2020 | 2330.94% | B. Riley Securities | $28 → $11 | Maintains | Buy |
| 02/04/2020 | 3877.9% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 01/30/2020 | 2993.92% | Cantor Fitzgerald | $59 → $14 | Assumes | → Overweight |
| 07/22/2019 | 5424.86% | Laidlaw & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/12/2018 | 6087.85% | B. Riley Securities | → $28 | Initiates Coverage On | → Buy |
| 07/20/2018 | 5645.86% | Raymond James | → $26 | Initiates Coverage On | → Outperform |
| 07/13/2018 | 7634.81% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 07/11/2018 | 12938.67% | Cantor Fitzgerald | → $59 | Initiates Coverage On | → Overweight |
| 06/13/2018 | 6529.83% | Maxim Group | $14 → $30 | Maintains | Buy |
| 03/15/2018 | — | Maxim Group | Upgrades | Hold → Buy | |
| 02/14/2018 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/15/2017 | 6971.82% | Roth Capital | → $32 | Initiates Coverage On | → Buy |
| 10/06/2017 | 4098.9% | Seaport Global | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/08/2022 | 120.99% | Canaccord Genu | 5 美元 → 1 美元 | 降级 | 买入 → 持有 |
| 05/18/2022 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
| 05/03/2022 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 05/03/2022 | 1004.97% | 雷蒙德·詹姆 | 14 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 05/17/2021 | 4540.88% | Canaccord Genu | 20 美元 → 21 美元 | 维护 | 买 |
| 03/19/2021 | 5424.86% | HC Wainwright & Co. | 29 美元 → 25 美元 | 维护 | 买 |
| 01/08/2021 | 3656.91% | 雷蒙德·詹姆 | 20 美元 → 17 美元 | 维护 | 跑赢大盘 |
| 11/25/2020 | 4319.89% | Canaccord Genu | 25 美元 → 20 美元 | 维护 | 买 |
| 05/22/2020 | 1667.96% | B. 莱利证券 | 11 美元 → 8 美元 | 降级 | 买入 → 中性 |
| 05/15/2020 | 4319.89% | 雷蒙德·詹姆 | 25 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 03/13/2020 | 5424.86% | Stifel | 35 美元 → 25 美元 | 维护 | 买 |
| 03/13/2020 | 2330.94% | B. 莱利证券 | 28 美元 → 11 美元 | 维护 | 买 |
| 02/04/2020 | 3877.9% | Craig-Hallum | → 18 美元 | 启动覆盖范围开启 | → 购买 |
| 01/30/2020 | 2993.92% | 坎托·菲茨杰拉德 | 59 美元 → 14 美元 | 假设 | → 超重 |
| 07/22/2019 | 5424.86% | Laidlaw & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 12/12/2018 | 6087.85% | B. 莱利证券 | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 07/20/2018 | 5645.86% | 雷蒙德·詹姆 | → 26 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 07/13/2018 | 7634.81% | Stifel | → 35 美元 | 启动覆盖范围开启 | → 购买 |
| 07/11/2018 | 12938.67% | 坎托·菲茨杰拉德 | → 59 美元 | 启动覆盖范围开启 | → 超重 |
| 06/13/2018 | 6529.83% | Maxim 集团 | 14 美元 → 30 美元 | 维护 | 买 |
| 03/15/2018 | — | Maxim 集团 | 升级 | 持有 → 买入 | |
| 02/14/2018 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 11/15/2017 | 6971.82% | 罗斯资本 | → 32 美元 | 启动覆盖范围开启 | → 购买 |
| 10/06/2017 | 4098.9% | 海港全球 | → 19 美元 | 启动覆盖范围开启 | → 购买 |
Galmed Pharmaceuticals Questions & Answers
高美药业问题与解答
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Canaccord Genuity on August 8, 2022. The analyst firm set a price target for $1.00 expecting GLMD to rise to within 12 months (a possible 120.99% upside). 4 analyst firms have reported ratings in the last year.
Canaccord Genuity于2022年8月8日公布了高美制药公司（纳斯达克股票代码：GLMD）的最新目标股价。该分析公司将目标股价定为1.00美元，预计GLMD将在12个月内升至12个月内（可能上涨120.99％）。去年有4家分析公司公布了评级。
The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Canaccord Genuity, and Galmed Pharmaceuticals downgraded their hold rating.
Canaccord Genuity对高美制药公司（纳斯达克股票代码：GLMD）的最新分析师评级由Canaccord Genuity提供，高美制药下调了持有评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on August 8, 2022 so you should expect the next rating to be made available sometime around August 8, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与高梅德制药公司的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Galmed Pharmicals的最新评级是在2022年8月8日公布的，因此您应该预计下一个评级将在2023年8月8日左右公布。
While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a downgraded with a price target of $5.00 to $1.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $0.45, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的高美制药（GLMD）评级已下调，目标股价为5.00美元至1.00美元。Galmed Pharmicals（GLMD）目前的交易价格为0.45美元，超出了分析师的预期区间。